Overview
- Multiple law firms have filed or are soliciting investors to move for lead‑plaintiff status in pending class actions that allege GRAIL misled the market about its NHS‑Galleri screening trial.
- The complaints cover purchases of GRAL stock from May 13, 2025 through February 19, 2026 and center on whether GRAIL overstated the trial’s design and prospects while withholding granular results.
- GRAIL disclosed top‑line NHS‑Galleri results on February 19, 2026 saying the trial failed to meet its primary endpoint and that a three‑year follow‑up may have been too short, a revelation that preceded a roughly 50.5% one‑day share collapse.
- Hagens Berman says its probe focuses on when GRAIL management knew a longer follow‑up would be necessary, and firms are advising potential whistleblowers and SEC contacts as part of ongoing investigations.
- Investors who bought during the alleged class period have until August 4, 2026 to seek lead‑plaintiff appointment; no class has been certified and the cases remain in early litigation and discovery stages.